Cell culture processes are used to produce the vast majority of protein therapeutics, valued at over US$180 billion per annum worldwide. For more than a decade now, these processes have become highly productive. To further enhance capital efficiency, there has been an increase in the adoption of disposable apparatus and continuous processing, as well as a greater exploration of in-line sensing, various -omic tools, and cell engineering to enhance process controllability and product quality consistency. These feats in cell culture processing for protein biologics will help accelerate the bioprocess advancements for virus and cell therapy applications.
Bibliographical noteFunding Information:
SAO was supported in part by the NIGMS Biotechnology Training Program ( T32GM008347-22) . This work was supported in part by NIIMBL PC2.1-042 .
© 2020 Elsevier Ltd